LUNGHIGH SIGNALFINANCIAL10-K

LUNG's market capitalization collapsed 57% while the company burned through significant cash reserves, showing severe financial deterioration despite modest revenue growth.

The dramatic decline in market value from $239.4M to $101.4M signals severe investor confidence loss, while the company's balance sheet deteriorated substantially with stockholders' equity falling 37% and current assets declining 25%. Despite growing revenue 8% to $90.5M and maintaining stable gross margins, the company continues burning cash with accumulated losses reaching $521.6M, indicating persistent operational challenges in achieving profitability.

Comparing 2026-03-10 vs 2025-02-25View on EDGAR →
FINANCIAL ANALYSIS

LUNG shows mixed operational performance with revenue growing 8% to $90.5M and net losses improving slightly from $56.4M to $54.0M, while R&D spending increased 11% to $19.5M. However, the balance sheet deteriorated significantly with current assets declining 25% to $101.7M, stockholders' equity falling 37% to $54.1M, and interest expense tripling to $3.2M, suggesting potential debt restructuring or refinancing. The reduced capital expenditures (-69%) combined with substantial asset declines signals cash conservation efforts amid mounting financial pressure.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
+203.2%
$1.1M$3.2M

Interest expense surged 203.2% — significant debt increase or rising rates materially impacting earnings.

Capital Expenditure
Cash Flow
-68.8%
$1.4M$452K

Capex reduced 68.8% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Stockholders Equity
Balance Sheet
-36.9%
$85.8M$54.1M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Current Assets
Balance Sheet
-25.4%
$136.2M$101.7M

Current assets declined 25.4% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-20.6%
$162.8M$129.3M

Total assets contracted 20.6% — asset sales, write-downs, or balance sheet optimization underway.

Current Liabilities
Balance Sheet
-17.9%
$24.4M$20.1M

Current liabilities reduced — improved short-term financial position and working capital health.

R&D Expense
P&L
+10.9%
$17.6M$19.5M

R&D investment increased 10.9% — signals commitment to future product development, though near-term margin impact.

LANGUAGE CHANGES
NEW — 2026-03-10
PRIOR — 2025-02-25
ADDED
The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant, based on the closing price of the shares of common stock on The Nasdaq Stock Market on June 30, 2025, was approximately $ 101.4 million.
trade policies and tariffs; our expectations regarding our ability to obtain and maintain intellectual property protection for our products, as well as our ability to operate our business without infringing the intellectual property rights of others; and our expectations regarding the impact of any public health crises on our business, financial condition and results of operations.
Our solution, which is comprised of the Zephyr Endobronchial Valve ( Zephyr Valve ), the Chartis Pulmonary Assessment System ( Chartis System ) and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches.
For the year ended December 31, 2025, we generated 95% of our revenue from markets where we sell directly.
We generated revenue of $90.5 million, with a gross margin of 74.2% and a net loss of $54.0 million, for the year ended December 31, 2025 compared to revenue of $83.8 million, with a gross margin of 74.0% and a net loss of $56.4 million, for the year ended December 31, 2024.
+7 more — sign up free →
REMOVED
The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant, based on the closing price of the shares of common stock on The Nasdaq Stock Market on June 28, 2024, was approximately $ 239.4 million.
Our solution, which is comprised of the Zephyr Endobronchial Valve ( Zephyr Valve ), the Chartis Pulmonary Assessment System ( Chartis System ) and the LungTraX Platform (which is called the StratX Platform in international markets), is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches.
For the year ended December 31, 2024, we generated 96% of our revenue from markets where we sell directly.
We generated revenue of $83.8 million, with a gross margin of 74.0% and a net loss of $56.4 million, for the year ended December 31, 2024 compared to revenue of $68.7 million, with a gross margin of 73.9% and a net loss of $60.8 million, for the year ended December 31, 2023.
As of December 31, 2024, we had an accumulated deficit of $467.6 million.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →